Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Lung cancer in patients with fibrosing interstitial lung diseases – An overview of current knowledge and challenges

Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U Wells, Manuela Funke-Chambour
ERJ Open Research 2022; DOI: 10.1183/23120541.00115-2022
Namrata Kewalramani
1Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Machahua
1Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
2Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venerino Poletti
3Department of Thoracic Diseases, “GB. Morgagni” Hospita, Forlì, Dipartimento di Medicina Specialistica Diagnostica e Sperimentale (DIMES) University of Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Cadranel
4Department of Pulmonary Medicine and Thoracic Oncology; Constitutive Reference Center of Rare Pulmonary Diseases, AP-HP, Hôpital Tenon and GRC04 Theranoscan, Sorbonne Université, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athol U Wells
5Royal Brompton and Harefield NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Funke-Chambour
1Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
2Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: manuela.funke-chambour@insel.ch
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Patients with progressive fibrosing interstitial lung diseases (fILD) have increased morbidity and mortality. Lung fibrosis can be associated with lung cancer (LC). The pathogenesis of both diseases shows similarities although not all mechanisms are understood. The combination of the diseases is challenging, due to its amplified risk of mortality and also because lung cancer treatment carries additional risks in patients with underlying lung fibrosis. Acute exacerbations in fILD patients are linked to increased mortality and the risk of acute exacerbations is increased after LC treatment with surgery, chemotherapy, or radiotherapy. Careful selection of treatment modalities is crucial to improve survival whilst maintaining acceptable quality of life in patients with combined LC and fILD. This overview of epidemiology, pathogenesis, treatment, and a possible role for antifibrotic drugs in patients with LC and fILD is the summary of a session presented during the virtual ERS conference 2021. The review summarises current knowledge and identifies areas of uncertainty. Most current data relate to patients with combined idiopathic pulmonary fibrosis and LC. There is a pressing need for additional prospective studies, required for the formulation of a consensus statement or guideline on the optimal care of patients with LC and fILD.

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Kewalramani reports grants and non-financial support from CSL Behring, from null, outside the submitted work.

Conflict of interest: Dr. Machahua has nothing to disclose.

Conflict of interest: Dr. POLETTI reports personal fees from Boerhinger Ing, personal fees from Roche, personal fees from AMBU, personal fees from ERBE, outside the submitted work.

Conflict of interest: Dr. Cadranel reports fees for participation to boards of experts for the development of cancer drugs from AbbVie, AZ, BI, BMS, Jansen, MSD, Novartis, Pfizer, Roche and Takeda.

Conflict of interest: Dr. Wells reports personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Bayer and Roche Pharmaceuticals, personal fees from Blade, outside the submitted work.

Conflict of interest: Dr. Funke-Chambour reports grants from Boehringer Ingelheim, grants from Roche, other from MSD, outside the submitted work.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received March 1, 2022.
  • Accepted April 18, 2022.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

PreviousNext
Back to top
Vol 8 Issue 2 Table of Contents
ERJ Open Research: 8 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lung cancer in patients with fibrosing interstitial lung diseases – An overview of current knowledge and challenges
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Lung cancer in patients with fibrosing interstitial lung diseases – An overview of current knowledge and challenges
Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U Wells, Manuela Funke-Chambour
ERJ Open Research Jan 2022, 00115-2022; DOI: 10.1183/23120541.00115-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lung cancer in patients with fibrosing interstitial lung diseases – An overview of current knowledge and challenges
Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U Wells, Manuela Funke-Chambour
ERJ Open Research Jan 2022, 00115-2022; DOI: 10.1183/23120541.00115-2022
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Current and Novel Treatment Options for OSA
  • Telemedicine and virtual respiratory care in the era of COVID-19
Show more Invited review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2022 by the European Respiratory Society